Trigeminal nerve-driven neurogenic inflammation linking migraine to glioblastoma invasion: a literature review.

Scientists have discovered a surprising connection between migraines and glioblastoma, an aggressive brain cancer. This literature review examined how nerves in the face and head—specifically the trigeminal nerve—may create inflammation that links these two conditions. When migraine occurs, this nerve releases chemical messengers called CGRP, substance P, and PACAP that cause pain. Researchers found these same chemicals may help brain tumors grow and spread by changing blood vessels, immune responses, and the tissue environment around tumors. Studies show people with migraines may have slightly higher rates of later brain tumor diagnosis, and imaging reveals tumors often spread along trigeminal nerve pathways. The research also explores repurposing migraine medications to fight cancer—drugs that block CGRP and substance P show promise in slowing tumor growth in laboratory studies. For acupuncture patients, this research is significant because acupuncture has established evidence for migraine prevention and may influence the same trigeminal nerve pathways and inflammatory chemicals discussed in this review. Acupuncture's ability to modulate CGRP and substance P release, reduce neurogenic inflammation, and calm overactive trigeminal nerves may offer benefits beyond pain relief. While this research doesn't suggest acupuncture treats brain cancer, it reinforces the importance of addressing chronic migraine and neuroinflammation through evidence-based approaches. Always seek care from a licensed acupuncturist with specialized training in headache disorders.

This literature review synthesizes evidence linking trigeminal nerve-driven neurogenic inflammation to both migraine pathophysiology and glioblastoma (GBM) progression. Activation of trigeminovascular afferents releases CGRP, substance P, and PACAP—neuropeptides that mediate migraine pain while simultaneously promoting tumor invasion through upregulation of matrix metalloproteinases, integrins, and cAMP-MAPK signaling pathways. Epidemiological data indicate elevated migraine prevalence in patients with subsequent brain tumor diagnosis, with MRI evidence of GBM spread along trigeminal pathways. Preclinical models demonstrate that NK1-receptor antagonists (aprepitant) and CGRP blockers (gepants) reduce GBM invasiveness and temozolomide resistance. Clinical relevance: trigeminal modulation via acupuncture may influence overlapping neuroinflammatory cascades implicated in chronic migraine. Practitioners should recognize the trigeminal-CGRP-substance P axis as a therapeutic target, though no sample sizes or effect measures were reported in this review article. Consider acupuncture's established migraine prevention efficacy within this emerging neuroinflammatory framework.